Elizabeth Jungman

Elizabeth Jungman

  • Director
  • Drug Safety & Innovation,
  • The Pew Charitable Trusts


Elizabeth Jungman directs Pew’s work on drug safety and innovation, overseeing Pew’s initiatives related to antibiotics and innovation, drug safety, and prescription drug abuse. Before joining Pew, she served as a senior health policy adviser with the Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012, the FDA provisions in the Pandemic All-Hazards Preparedness Reauthorization Act of 2013, and the Drug Quality and Security Act of 2013, which included drug compounding and supply chain security measures. Before moving to the Hill, Jungman was in private legal practice, where she counseled clients on a broad range of FDA regulatory matters and other health care issues related to the human pharmaceutical industry. She has an undergraduate biology degree from Harvard College, a J.D. from Georgetown University, and a master’s degree in public health from Johns Hopkins University. 

Recent Work

View All
  • Pharmacy Implementation of the Drug Supply Chain Security Act

    The Drug Supply Chain Security Act (DSCSA) of 2013 created a national system in which companies involved in pharmaceutical distribution work together to safeguard the U.S. pharmaceutical supply and protect consumers from compromised or counterfeit drugs. Pharmacies play a critical role in preventing unsafe products from reaching consumers. Read More

  • Comments to FDA on 503B Quality Standards Draft Guidance

    On September 2, Pew submitted comments to the U.S. Food and Drug Administration in response to draft guidance on the implementation of Title I of the Drug Quality and Security Act. The comments highlight the need for more robust safeguards when compounding occurs on a larger scale and reference the Pew commissioned report “Ensuring the Safety of Compounded Drugs: Study highlights key... Read More

  • Pew and Partners Comment on FDA’s Suspect Product Guidance

    On Monday, August 11, The Pew Charitable Trusts submitted comments on draft guidance documents from the U.S. Food and Drug Administration on how supply chain partners will identify and notify other partners of “suspect product,” part of Title II of the Drug Quality and Security Act, Drug Supply Chain Security Act. Read More

Media Contact

Linda Paris

Officer, Communications